Source:http://linkedlifedata.com/resource/pubmed/id/16335526
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
2005-12-12
|
pubmed:abstractText |
Knocking out the regulatory beta subunit of protein kinase CK2 in mice leads to early embryonic lethality. Heterozygous CK2beta (CK2beta+/-) knockout mice do not show an obvious phenotype. However, the number of heterozygous offsprings from CK2B+/- inter-crossings is lower than expected, meaning that some heterozygous embryos do not survive. Interestingly, CK2beta+/- ES (Embryonic Stem) cells express a considerably lower level of CK2beta than wild-type ES cells, whereas the level of CK2beta in organs from heterozygous adult mice does not significantly differ from those of wild-type mice. The data suggest a compensatory mechanism that adjusts CK2beta levels during development in the majority of, but not in all, cases (Mol Cell Biol 23: 908-915, 2003). In order to find an explanation for the gene dosage effect observed for heterozygous offsprings, we analysed embryos at mid-gestation (E10.5) as well as wild-type and CK2beta+/- ES cells for differences in growth rate and response to different stress agents. Analysis of E10.5 embryos generated from heterozygous matings revealed about 20% of smaller retarded CK2beta+/- embryos. No correlation between CK2beta levels in normal looking and retarded CK2beta+/- embryos were found. However, a different post-translational form of CK2beta protein has been detected in these retarded embryos. Cellular parameters such as growth rate and G1-, G2-checkpoints in ES cells were identical in both wild-type and CK2beta+/- cells. When ES cells were injected to induce differentiated teratocarcinoma in syngenic mice, the size of the tumours correlated with the level of CK2beta.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0300-8177
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
274
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
31-7
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:16335526-Animals,
pubmed-meshheading:16335526-Casein Kinase II,
pubmed-meshheading:16335526-Cell Cycle,
pubmed-meshheading:16335526-Embryo, Mammalian,
pubmed-meshheading:16335526-Gene Dosage,
pubmed-meshheading:16335526-Heterozygote,
pubmed-meshheading:16335526-Mice,
pubmed-meshheading:16335526-Mice, Knockout,
pubmed-meshheading:16335526-Phenotype,
pubmed-meshheading:16335526-Protein Subunits,
pubmed-meshheading:16335526-Stem Cells,
pubmed-meshheading:16335526-Teratocarcinoma
|
pubmed:year |
2005
|
pubmed:articleTitle |
Knocking out the regulatory beta subunit of protein kinase CK2 in mice: gene dosage effects in ES cells and embryos.
|
pubmed:affiliation |
DRDC/TS-INSERM EMI104, CEA Grenoble, Grenoble, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|